CDC42BPA

Across TCGA pan-cancer cohorts, CDC42BPA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDC42BPA data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CDC42BPA mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDC42BPA expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LSCC, HNSC, and PDAC are the cancer types where CDC42BPA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.606	0.948	<.001	40	view →
HNSC	OS	Median	II,III,IV	0.632	0.810	.022	36	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	12	view →
CCRCC	OS	Median	IV	0.150	0.785	.040	4	view →
LUAD	OS	Quartile	All	0.946	0.789	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDC42BPA–LSCC (DFS)

Open the LSCC breakdown →